Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 2
1987 1
1988 1
1989 2
1990 2
1991 4
1992 1
1993 2
1994 2
1995 5
1996 5
1997 5
1998 5
1999 2
2000 3
2002 5
2003 10
2004 4
2005 11
2006 17
2007 8
2008 8
2009 14
2010 29
2011 24
2012 22
2013 35
2014 43
2015 28
2016 34
2017 36
2018 42
2019 56
2020 64
2021 68
2022 64
2023 87
2024 50

Text availability

Article attribute

Article type

Publication date

Search Results

726 results

Results by year

Filters applied: . Clear all
Page 1
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial.
Shitara K, Lordick F, Bang YJ, Enzinger P, Ilson D, Shah MA, Van Cutsem E, Xu RH, Aprile G, Xu J, Chao J, Pazo-Cid R, Kang YK, Yang J, Moran D, Bhattacharya P, Arozullah A, Park JW, Oh M, Ajani JA. Shitara K, et al. Among authors: xu rh. Lancet. 2023 May 20;401(10389):1655-1668. doi: 10.1016/S0140-6736(23)00620-7. Epub 2023 Apr 15. Lancet. 2023. PMID: 37068504 Clinical Trial.
Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial.
Shah MA, Shitara K, Ajani JA, Bang YJ, Enzinger P, Ilson D, Lordick F, Van Cutsem E, Gallego Plazas J, Huang J, Shen L, Oh SC, Sunpaweravong P, Soo Hoo HF, Turk HM, Oh M, Park JW, Moran D, Bhattacharya P, Arozullah A, Xu RH. Shah MA, et al. Among authors: xu rh. Nat Med. 2023 Aug;29(8):2133-2141. doi: 10.1038/s41591-023-02465-7. Epub 2023 Jul 31. Nat Med. 2023. PMID: 37524953 Free PMC article. Clinical Trial.
Liquid Biopsy of Methylation Biomarkers in Cell-Free DNA.
Luo H, Wei W, Ye Z, Zheng J, Xu RH. Luo H, et al. Among authors: xu rh. Trends Mol Med. 2021 May;27(5):482-500. doi: 10.1016/j.molmed.2020.12.011. Epub 2021 Jan 23. Trends Mol Med. 2021. PMID: 33500194 Review.
Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial.
Mai HQ, Chen QY, Chen D, Hu C, Yang K, Wen J, Li J, Shi Y, Jin F, Xu R, Pan J, Qu S, Li P, Hu C, Liu YC, Jiang Y, He X, Wang HM, Lim WT, Liao W, He X, Chen X, Wang S, Yuan X, Li Q, Lin X, Jing S, Chen Y, Lu Y, Hsieh CY, Yang MH, Yen CJ, Samol J, Luo X, Wang X, Tang X, Feng H, Yao S, Keegan P, Xu RH. Mai HQ, et al. Among authors: xu rh. JAMA. 2023 Nov 28;330(20):1961-1970. doi: 10.1001/jama.2023.20181. JAMA. 2023. PMID: 38015220 Free PMC article. Clinical Trial.
726 results